ArticleHealth science reports2026
Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Fitusiran is a first-in-class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor-independent prophylaxis. This commentary aims to summarize the clinical evidence supporting fitusiran, highlight its therapeutic significance, and discuss its potential advantages and safety considerations. Methods: This commentary reviews key findings from Phase 1-3 clinical trials, including ATLAS-INH and ATLAS-PPX, as well as regulatory documents and published pharmacologic evaluations. Evidence on annualized bleeding rate (ABR) reduction, thrombin generation, safety outcomes, and patient-reported benefits was synthesized to assess the impact of AT suppression on bleed prevention. Results: Across clinical development, fitusiran produced substantial reductions in bleeding rates in Hemophilia A and B, irrespective of inhibitor status. Phase 1 and 2 trials demonstrated > 70%-80% AT suppression with marked increases in thrombin generation. In Phase 3 trials, median ABR decreased from 17.7 to 0.0 in ATLAS-INH and by approximately 65% in ATLAS-PPX after switching from standard prophylaxis. Many participants remained completely bleed-free. Safety findings included reversible elevations in liver enzymes, mild injection-site reactions, headaches, and rare thrombotic events, necessitating AT-level and hepatic monitoring. Conclusion: Fitusiran offers a transformative, once-monthly prophylactic option with broad applicability across hemophilia types and inhibitor status. Its RNAi-based, factor-independent mechanism enables durable bleed protection and improved treatment convenience. While long-term hepatic safety and thrombotic risk require continued surveillance, fitusiran represents a significant advance in hemophilia management and a promising step toward more accessible, individualized, and rebalancing-based therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.